TheraCryf (LSE:TCF) LT-Debt-to-Total-Asset: 0.00 (As of Sep. 2025)


What is TheraCryf LT-Debt-to-Total-Asset?

TheraCryf LSE:TCF LT-Debt-to-Total-Asset is 0.00 as of Sep. 2025. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. TheraCryf's long-term debt to total assests ratio for the quarter that ended in Sep. 2025 was 0.00.

TheraCryf's long-term debt to total assets ratio stayed the same from Sep. 2024 (0.00) to Sep. 2025 (0.00).

TheraCryf  (LSE:TCF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

TheraCryf LT-Debt-to-Total-Asset Related Terms

TheraCryf LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for TheraCryf's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf LT-Debt-to-Total-Asset Chart

TheraCryf Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TheraCryf Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TheraCryf LT-Debt-to-Total-Asset Calculation

TheraCryf's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (A: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2025 )/Total Assets (A: Mar. 2025 )
=0/7.63
=

TheraCryf's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (Q: Sep. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2025 )/Total Assets (Q: Sep. 2025 )
=0/6.618
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
TheraCryf (LSE:TCF) has a LT-Debt-to-Total-Asset of 0.00 as of Sep. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TheraCryf and its competitors.
Is TheraCryf's LT-Debt-to-Total-Asset too high?
TheraCryf's current LT-Debt-to-Total-Asset is 0.00.
How does TheraCryf's LT-Debt-to-Total-Asset compare to VRTX and REGN?
TheraCryf's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TheraCryf and its competitors. TheraCryf's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TheraCryf stock overvalued right now?
TheraCryf (LSE:TCF) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For TheraCryf (LSE:TCF), the current LT-Debt-to-Total-Asset is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TheraCryf Business Description

Address Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.